A Phase 2 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis

Inclusion Criteria: * Stable CKD patients who are currently on hemodialysis three times a week for at least 12 weeks prior to the acquisition of informed consent * Patients on stable dose(s) of phosphate binder(s) for at least 28 days prior to the acquisition of informed consent. * Patients on stable dose(s) of Vitamin D or calcitonin agent for at least 28 days prior to the acquisition of informed consent, in case patients are treated by those agents Exclusion Criteria: * History of major gastrointestinal surgery, or swallowing disorders, bowel obstruction, hemorrhagic gastrointestinal lesion * Continuous severe constipation/diarrhea. * History of parathyroid intervention \[parathyroidectomy（PTx），percutaneous ethanol injection therapy（PEIT）etc.\] within 1 year of the acquisition of informed consent * Diet restriction such as fasting and/or excessive dieting * Uncontrolled hypertension